221 related articles for article (PubMed ID: 31502382)
1. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
Dore MP; Bibbò S; Loria M; Salis R; Manca A; Pes GM; Graham DY
Helicobacter; 2019 Dec; 24(6):e12659. PubMed ID: 31502382
[TBL] [Abstract][Full Text] [Related]
2. Metagenomic Changes of Gut Microbiota following Treatment of
Dore MP; Sau R; Niolu C; Abbondio M; Tanca A; Bibbò S; Loria M; Pes GM; Uzzau S
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889746
[TBL] [Abstract][Full Text] [Related]
3. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study.
Poonyam P; Chotivitayatarakorn P; Vilaichone RK
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2859-2864. PubMed ID: 31554388
[TBL] [Abstract][Full Text] [Related]
4. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
[TBL] [Abstract][Full Text] [Related]
5. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
6. Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Zullo A; De Francesco V; Bellesia A; Vassallo R; D'Angelo A; Scaccianoce G; Sacco R; Bresci G; Eramo A; Tanzilli A; Ridola L; Alvaro D; Londoni C; Brambilla G; Manta R; Di Ciaula A; Portincasa P
J Gastrointestin Liver Dis; 2017 Sep; 26(3):225-229. PubMed ID: 28922433
[TBL] [Abstract][Full Text] [Related]
7. Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series.
Dore MP; Soro S; Rocchi C; Loria MF; Bibbò S; Pes GM
Medicine (Baltimore); 2016 Apr; 95(15):e3411. PubMed ID: 27082621
[TBL] [Abstract][Full Text] [Related]
8. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
9. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Nyssen OP; Perez-Aisa A; Rodrigo L; Castro M; Mata Romero P; Ortuño J; Barrio J; Huguet JM; Modollel I; Alcaide N; Lucendo A; Calvet X; Perona M; Gomez B; Gomez Rodriguez BJ; Varela P; Jimenez-Moreno M; Dominguez-Cajal M; Pozzati L; Burgos D; Bujanda L; Hinojosa J; Molina-Infante J; Di Maira T; Ferrer L; Fernández-Salazar L; Figuerola A; Tito L; de la Coba C; Gomez-Camarero J; Fernandez N; Caldas M; Garre A; Resina E; Puig I; O'Morain C; Megraud F; Gisbert JP
Helicobacter; 2020 Oct; 25(5):e12722. PubMed ID: 32656898
[TBL] [Abstract][Full Text] [Related]
10. Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera®) to eradicate Helicobacter pylori infection in 200 patients.
Castro Fernández M; Romero García T; Keco Huerga A; Pabón Jaén M; Lamas Rojas E; Llorca Fernández R; Grande Santamaría L; Rojas Feria M
Rev Esp Enferm Dig; 2019 Jun; 111(6):467-470. PubMed ID: 31117799
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
Kim JY; Lee SY; Kim JH; Sung IK; Park HS
Helicobacter; 2020 Apr; 25(2):e12683. PubMed ID: 32074663
[TBL] [Abstract][Full Text] [Related]
12. Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice.
Pérez-Arellano E; Rodriguez-Garcia MI; Galera Rodenas AB; de la Morena-Madrigal E
Gastroenterol Hepatol; 2018 Mar; 41(3):145-152. PubMed ID: 29054320
[TBL] [Abstract][Full Text] [Related]
13. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
14. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Dore MP; Farina V; Cuccu M; Mameli L; Massarelli G; Graham DY
Helicobacter; 2011 Aug; 16(4):295-300. PubMed ID: 21762269
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Shaikh T; Fallone CA
Can J Gastroenterol Hepatol; 2016; 2016():7321574. PubMed ID: 27446864
[TBL] [Abstract][Full Text] [Related]
17. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera
Rodríguez de Santiago E; Martín de Argila de Prados C; Marcos Prieto HM; Jorge Turrión MÃ; Barreiro Alonso E; Flores de Miguel A; de la Coba Ortiz C; Rodríguez Escaja C; Pérez Álvarez G; Ferre Aracil C; Aguilera Castro L; García García de Paredes A; Rodríguez Pérez A; Albillos Martínez A
Helicobacter; 2017 Oct; 22(5):. PubMed ID: 28771880
[TBL] [Abstract][Full Text] [Related]
18. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial.
Lim H; Bang CS; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Medicine (Baltimore); 2018 Nov; 97(46):e13245. PubMed ID: 30431605
[TBL] [Abstract][Full Text] [Related]
19. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.
Fiorini G; Saracino IM; Zullo A; Gatta L; Pavoni M; Vaira D
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 29094477
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
